Thymosin alpha-1 is a naturally occurring peptide produced by the thymus gland, essential for immune system development and function. It primarily enhances T-cell maturation and activity, particularly CD4+ helper T cells, cytotoxic T cells, and natural killer cells. By bolstering cellular immunity, it may help combat immunosenescence, the age-related decline in immune function, potentially improving resilience against infections and contributing to healthy aging.
Verdict
Modulates immunity; potential for healthy aging, requires injection.
HEALTHSPAN IMPACT
Moderate
RISK LEVEL
Moderate
EVIDENCE GRADE
B
MONTHLY COST
$200 - $600
Protocol
- For healthspan-focused immune modulation, doses typically range from 0.8 mg to 3.2 mg administered via subcutaneous injection 1-2 times per week.
- For approved indications (e.g., chronic hepatitis B), standard protocols include 1.6 mg subcutaneous injection twice weekly for 6-12 months.
Flags
- Not FDA approved for general healthspan or anti-aging in the US.
- Requires subcutaneous injection, necessitating proper sterile technique and medical oversight.
- May interact with other immunosuppressants or immune-stimulants, requiring caution.
- Long-term safety data in healthy individuals for healthspan applications is limited.
- Contraindicated in individuals with hypersensitivity or autoimmune diseases where immune stimulation is undesirable.